which was approved for SBS in adults in 2012 and children in 2019 – while AstraZeneca's GLP-1 drug Byetta/Bydureon (exenatide) has also been used off-label to treat the disorder. 9 Meters is ...

The EC made its decision based on data from DURATION-NEO-1 clinical trial comparing Bydureon BCise and AZ'[s twice-daily exenatide formulation, Byetta. After 28 weeks of treatment, patients ...

The drugs selected for the report include Mounjaro, Rybelsus, Ozempic, Trulicity, Bydureon, Victoza, Byetta, Invokana, Jardiance and Farxiga. Currently, Medicare Part D covers diabetes drugs for ...